Veraxa Biotech AG - Post de-SPAC Stock: price and insider trades · United States
4 insiders bought €109k of shares over the last 90 days, the latest by Gruninger Marc, filed 29 Oct 2026.
Cluster: 2 buyers in 30 daysVeraxa Biotech AG - Post de-SPAC: what insiders have been doing
Veraxa Biotech AG - Post de-SPAC is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 29 October 2026, 5 filings were filed, from 4 insiders.
Not one open-market sale was filed. On the buying side, 4 insiders reported 5 purchases totalling €109k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Those buying include 3 senior executives and 1 chief executive. The largest single trade was a purchase of €64k by Baumann Oliver Rolf, published on 31 August 2026, equal to 0.037% of the market capitalisation.
The last insider purchase was made public on 29 October 2026, 10 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade.
For context, the typical company on the same exchange (median of 3,171 companies) published 24 filings over the same period, against 5 filings here. The full history, which starts in 2026, counts 5 purchases against no sales.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- -26.4%Entry US$1.40 · Close 22 Oct 2026 US$1.03
- -26.4%Entry US$1.40 · Close 22 Oct 2026 US$1.03
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 867 shares@ US$0.98Ordinary SharesSEC:0001829126-26-011778:0Canonical exit: 25 Jan 2027 (T+90)
- 9,133 shares@ US$1.00Ordinary SharesSEC:0001829126-26-011778:1Canonical exit: 26 Jan 2027 (T+90)
- 30,000 shares@ US$1.090.023% mcap100.0% of flowOrdinary SharesSEC:0001829126-26-011387:0Canonical exit: 18 Jan 2027 (T+90)
- 50,000 shares@ US$1.500.037% mcap100.0% of flowOrdinary SharesSEC:0001829126-26-009544:0Canonical exit: 25 Nov 2026 (T+90)
- 5,000 shares@ US$1.530.0037% mcap100.0% of flowOrdinary SharesSEC:0001829126-26-009543:0Canonical exit: 25 Nov 2026 (T+90)
5 of 5 declarations
About Veraxa Biotech AG - Post de-SPAC
Veraxa Biotech AG is a biotechnology company that has recently completed a merger with a special purpose acquisition company. It is listed on NASDAQ under the ticker XNAS.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
